CAN 10
Alternative Names: CAN-10Latest Information Update: 10 Dec 2024
At a glance
- Originator Lund University
- Developer Cantargia
- Class Anti-inflammatories; Antipsoriatics; Cardiovascular therapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Interleukin 1 inhibitors; Interleukin 36 inhibitors; Interleukin-33 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Myocarditis; Plaque psoriasis; Systemic scleroderma
- Preclinical Atherosclerosis; Peritonitis; Psoriatic arthritis
Most Recent Events
- 29 Nov 2024 Cantargia plans a phase II trial for Plaque psoriasis in H2 2025
- 20 Oct 2023 Phase-I clinical trials in Myocarditis in Sweden (IV), prior to October 2023 (Cantargia pipeline, October 2023)
- 20 Oct 2023 Phase-I clinical trials in Myocarditis in Sweden (SC), prior to October 2023 (Cantargia pipeline, October 2023)